Posterior reversible encephalopathy syndrome and anti-angiogenic agents: a case report

Detalhes bibliográficos
Autor(a) principal: Silva, F
Data de Publicação: 2011
Outros Autores: Pêgo, P, Vendrell, MC, Farias, MJ, Timóteo, A, Costa, MC, Cravo, I, Gomes, F
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10400.10/464
Resumo: Posterior reversible encephalopathy syndrome is an increasingly recognised clinico-radiological entity, associated with several medical conditions (such as systemic arterial hypertension) and characterised by seizures, altered mental status, headaches, and visual symptoms. Magnetic resonance imaging is a key component in this diagnosis, with hyperintense foci in T2-weighted images, corresponding to vasogenic oedema. The pathophysiology is not fully understood but probably involves loss of auto-regulation of cerebral vasculature or endothelial dysfunction or both. A 56-year-old male, suffering from a gastro-intestinal stromal tumour with hepatic metastasis resistant to imatinib, on therapy with sunitinib, came to the Emergency Department because of headaches, hallucinations, and loss of vision. There was no previous history of high blood pressure. A hypertensive crisis was diagnosed; ophthalmological examination on admission showed no light perception bilaterally. Brain imaging displayed bilateral parieto-occipital and frontal vasogenic oedema, consistent with the clinical diagnosis of posterior reversible encephalopathy syndrome. After treatment of hypertension and suspension of sunitinib, the patient recovered from his symptoms. Control imaging showed no oedema. Angiogenesis inhibitors, such as sunitinib and bevacizumab, can cause hypertension, one of the many medical conditions associated with the posterior reversible encephalopathy syndrome. This syndrome should be considered in cases of acute visual loss, particularly in view of its reversible nature when diagnosed and treated promptly.
id RCAP_194bb88a9ef859b915282a3dc341454d
oai_identifier_str oai:repositorio.hff.min-saude.pt:10400.10/464
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Posterior reversible encephalopathy syndrome and anti-angiogenic agents: a case reportSíndrome da leucoencefalopatia posteriorInibidores da angiogêneseBevacizumabPosterior reversible encephalopathy syndromeSunitinibAnti-angiogenic agentsPosterior reversible encephalopathy syndrome is an increasingly recognised clinico-radiological entity, associated with several medical conditions (such as systemic arterial hypertension) and characterised by seizures, altered mental status, headaches, and visual symptoms. Magnetic resonance imaging is a key component in this diagnosis, with hyperintense foci in T2-weighted images, corresponding to vasogenic oedema. The pathophysiology is not fully understood but probably involves loss of auto-regulation of cerebral vasculature or endothelial dysfunction or both. A 56-year-old male, suffering from a gastro-intestinal stromal tumour with hepatic metastasis resistant to imatinib, on therapy with sunitinib, came to the Emergency Department because of headaches, hallucinations, and loss of vision. There was no previous history of high blood pressure. A hypertensive crisis was diagnosed; ophthalmological examination on admission showed no light perception bilaterally. Brain imaging displayed bilateral parieto-occipital and frontal vasogenic oedema, consistent with the clinical diagnosis of posterior reversible encephalopathy syndrome. After treatment of hypertension and suspension of sunitinib, the patient recovered from his symptoms. Control imaging showed no oedema. Angiogenesis inhibitors, such as sunitinib and bevacizumab, can cause hypertension, one of the many medical conditions associated with the posterior reversible encephalopathy syndrome. This syndrome should be considered in cases of acute visual loss, particularly in view of its reversible nature when diagnosed and treated promptly.Informa HealthcareRepositório do Hospital Prof. Doutor Fernando FonsecaSilva, FPêgo, PVendrell, MCFarias, MJTimóteo, ACosta, MCCravo, IGomes, F2012-02-01T11:02:55Z2011-01-01T00:00:00Z2011-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.10/464engNeuro-ophthalmology. 2011; 35(1): 32–371744-506Xinfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2022-09-20T15:51:23Zoai:repositorio.hff.min-saude.pt:10400.10/464Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T15:51:45.237519Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Posterior reversible encephalopathy syndrome and anti-angiogenic agents: a case report
title Posterior reversible encephalopathy syndrome and anti-angiogenic agents: a case report
spellingShingle Posterior reversible encephalopathy syndrome and anti-angiogenic agents: a case report
Silva, F
Síndrome da leucoencefalopatia posterior
Inibidores da angiogênese
Bevacizumab
Posterior reversible encephalopathy syndrome
Sunitinib
Anti-angiogenic agents
title_short Posterior reversible encephalopathy syndrome and anti-angiogenic agents: a case report
title_full Posterior reversible encephalopathy syndrome and anti-angiogenic agents: a case report
title_fullStr Posterior reversible encephalopathy syndrome and anti-angiogenic agents: a case report
title_full_unstemmed Posterior reversible encephalopathy syndrome and anti-angiogenic agents: a case report
title_sort Posterior reversible encephalopathy syndrome and anti-angiogenic agents: a case report
author Silva, F
author_facet Silva, F
Pêgo, P
Vendrell, MC
Farias, MJ
Timóteo, A
Costa, MC
Cravo, I
Gomes, F
author_role author
author2 Pêgo, P
Vendrell, MC
Farias, MJ
Timóteo, A
Costa, MC
Cravo, I
Gomes, F
author2_role author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Repositório do Hospital Prof. Doutor Fernando Fonseca
dc.contributor.author.fl_str_mv Silva, F
Pêgo, P
Vendrell, MC
Farias, MJ
Timóteo, A
Costa, MC
Cravo, I
Gomes, F
dc.subject.por.fl_str_mv Síndrome da leucoencefalopatia posterior
Inibidores da angiogênese
Bevacizumab
Posterior reversible encephalopathy syndrome
Sunitinib
Anti-angiogenic agents
topic Síndrome da leucoencefalopatia posterior
Inibidores da angiogênese
Bevacizumab
Posterior reversible encephalopathy syndrome
Sunitinib
Anti-angiogenic agents
description Posterior reversible encephalopathy syndrome is an increasingly recognised clinico-radiological entity, associated with several medical conditions (such as systemic arterial hypertension) and characterised by seizures, altered mental status, headaches, and visual symptoms. Magnetic resonance imaging is a key component in this diagnosis, with hyperintense foci in T2-weighted images, corresponding to vasogenic oedema. The pathophysiology is not fully understood but probably involves loss of auto-regulation of cerebral vasculature or endothelial dysfunction or both. A 56-year-old male, suffering from a gastro-intestinal stromal tumour with hepatic metastasis resistant to imatinib, on therapy with sunitinib, came to the Emergency Department because of headaches, hallucinations, and loss of vision. There was no previous history of high blood pressure. A hypertensive crisis was diagnosed; ophthalmological examination on admission showed no light perception bilaterally. Brain imaging displayed bilateral parieto-occipital and frontal vasogenic oedema, consistent with the clinical diagnosis of posterior reversible encephalopathy syndrome. After treatment of hypertension and suspension of sunitinib, the patient recovered from his symptoms. Control imaging showed no oedema. Angiogenesis inhibitors, such as sunitinib and bevacizumab, can cause hypertension, one of the many medical conditions associated with the posterior reversible encephalopathy syndrome. This syndrome should be considered in cases of acute visual loss, particularly in view of its reversible nature when diagnosed and treated promptly.
publishDate 2011
dc.date.none.fl_str_mv 2011-01-01T00:00:00Z
2011-01-01T00:00:00Z
2012-02-01T11:02:55Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10400.10/464
url http://hdl.handle.net/10400.10/464
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Neuro-ophthalmology. 2011; 35(1): 32–37
1744-506X
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Informa Healthcare
publisher.none.fl_str_mv Informa Healthcare
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799130381160546304